American Cyanamid Company

Other

Essential Therapeutics, Inc.

May D Lee

Donald B Borders

Raymond T Testa

David P Labeda

Amedeo A Fantini

William M Maiese

Raymond C Yao

Michael Greenstein

John H Martin

Jane P Kirby

Olga Lomovskaya

Suzanne Chamberland

Mary P Lechevalier

Peter T Northcote

Jorge L Gallazzo

The present invention provides a novel strain of , means for identifying it, methods for culturing it at several different levels, two new antibiotics derived from the cultures and the physico-chemical characteristics of those compounds and their biological activity against a variety of microorganisms.

Antibiotics from microbispora

The use of compounds of the milbemycin class as inhibitors of efflux pumps in microbes or other cells is described, along with pharmaceutical compositions incorporating a milbemycin. Also described is a method of screening for compounds which inhibit a CDR1, CDR2, BEN, or FLU1 efflux pump or a pump with components having a high level of protein level sequence similarity with the components of those efflux pumps.

Fungal efflux pump inhibitors

A new method of producing a mixture of gibberellins which is predominantly GA,and GA,but also contains GA,has the steps of providing a seed of,Strain LTB-1027 or mutants derived therefrom, inoculating the seed into a culture medium rich in carbohydrate and relatively low in nitrogen, incubating the culture for at least four days, separating the,Strain LTB-1027 from the culture broth, and extracting the gibberellins to produce a gibberellin mixture which is at least 50% GA,and GA,. The method produces a gibberellin mixture in which the combined titer of GA,and GA,exceeds 800 mg/liter. The production method also produces a gibberellin mixture with approximately equal titers of gibberellins GA,and GA,. A variation of the method produces a gibberellin mixture which contains over 40% GA,.

Production of high titers of gibberellins, GA4 and GA7, by Gibberella fujikuroi strain LTB-1027

This invention relates to the antibiotics LL-14E605.beta. and O-methyl-LL-14E605.beta. derived from the microorganism Sebekia benihana which are useful as antibacterial agents.

Antibiotic LL-14E605.beta. and O-methyl-LL-14E605.beta.

Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora spp. calichensis NRRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Antitumor antibiotics (LL-E33288 complex)

The invention is N-acyl and dihydro-N-acyl analogs of the family of antibacterial and antitumor agents known collectively as the E33288 complex.

N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition

Dihydro derivatives of LL-E33288, BBM-1075 FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed and described, including the degradation product of LL-E33288 antibiotics/antitumor agents dihydro-LL-E33288-pseudoaglycone.

Dihydro derivatives of LL-E33288 antibiotics

Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora ssp. calichensis NNRL-15839, NRRL-15975 and NRRL-18149, are disclosed.

Degradation products, termed pseudaglycones, of LL-E33288, BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed anad described.

Pseudoaglycones of LL-E33288 antibiotics

A new antibacterial agent designated LL-C19004 is described, which antibacterial agent is produced through microbiological fermentation, under controlled conditions using a new species of Saccharothrix, Saccharothrix espanaensis (NRRL 15764).

Antibiotic LL-C19004

This invention relates to new polypeptide antibiotics designated LL-BO2964.alpha., LL-BO2964.beta., LL-BO2964.gamma., and a mixture thereof designated LL-BO2964, produced during microbiological fermentation, under controlled conditions, using a new strain of Streptomyces coeruleorubidus subspecies rubidus or a mutant thereof. The new antibiotics are active against a variety of microorganisms and are also useful in treating tuberculosis.

Antibiotic agents from S. coeruleorubidus, rubidus

Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1, LL-D49194.beta..sub.2, LL-D49194.beta..sub.3, LL-D49194.gamma., LL-D49194.delta., LL-D49194.epsilon., LL-D49194.xi., LL-D49194.eta., LL-D49194.omega., LL-D49194.omega..sub.2 and LL-D49194.omega..sub.3.

Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1,

This disclosure describes a new antibacterial and anti-tumor agent designated LL-D05139.beta., produced in a microbiological fermentation under controlled conditions using a new genus Glycomyces harbinensis gen. nov., sp. nov., and mutants thereof.

Preparation of antibiotic LL-D05139.beta. from cultures of Glycomyces

This disclosure describes a new antibacterial and anti-tumor agent designated LL-D05139 .beta., produced in a microbiological fermentation under controlled conditions using a new genus Glycomyces harbinensis gen. nov., sp. nov., and mutants thereof.

Growing community of inventors

Monsey, NY, United States of America

May D Lee